# Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/hematologic-malignancies-regulatory-considerations-for-use-of-minimal-residual-disease-in-development-of-drug-and-biological-products-for-treatment-guidance-for-industry/5e0485fc-a570-4965-bae5-05741639f886

> FDA guidance document: Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment:  Guidance for Industry. Issue date: January 24, 2020. Get complete insights and analysis.

---

## Details

- Title: Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2020-01-24
- Last Changed: 2020-01-24
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-3090">FDA-2018-D-3090</a>

## Related Documents

- [Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/bladder-cancer-developing-drugs-and-biologics-for-adjuvant-treatment-guidance-for-industry/b3fd959c-72c5-4e86-a4a9-5fa31d0ce7b7)
- [Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/renal-cell-carcinoma-developing-drugs-and-biologics-for-adjuvant-treatment-guidance-for-industry/db30c852-ed7b-4054-8906-3aadd3851179)
- [Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment:  Guidance for Industry; Availability](https://www.globalkeysolutions.net/guidances/guidance-document/acute-myeloid-leukemia-developing-drugs-and-biological-products-for-treatment-guidance-for-industry-availability/7511194b-76aa-4116-a433-198583956923)